Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 50.0% from a year ago
Common stock stood at $6K at the end of Q1 FY2026, up 50.0% from a year earlier and up 20.0% from the prior quarter.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +50.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 5K USD
- Year-over-year change
- +25.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5K | +25.0% |
| FY2024 | 2024-12-31 | 4K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Common Stock vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 common stock of $6K is the 5th highest of the 8 companies compared; the peer median is $20K.
- Its year-over-year change of +50.0% is the highest of 7, against a peer median of +5.4%.
- Common stock amounts to 0.0% of total assets for ZBIO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $162K | +48.6% | +45.9% | 0.1% | |
| Dec 2025 | $121K | +9.0% | +5.9% | 1.1% | |
UPBUpstream Bio, Inc. | Mar 2026 | $54K | +1.9% | +162.1% | 0.0% |
| Sep 2026 | $20K | +17.6% | +15.4% | 0.0% | |
| Mar 2026 | $6K | +50.0% | — | 0.0% | |
| Mar 2026 | $2K | +0.0% | -30.7% | 0.0% | |
| Mar 2026 | $1K | +0.0% | +0.0% | 0.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding ZBIO) | $20K | +5.4% | +10.7% | 0.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.